Barclays initiated coverage of British veterinary services operator CVS Group Plc at an "equal weight" rating and assigned a price target of 1,340 pence. The broker said the recent acquisitions in Australia are expected to generate post-tax returns that sit below Barclays’ estimates of the company’s cost of capital, while competitive pressures in the UK and constrained near-term trading visibility limit upside.
Shares of CVS were priced at 1,182 pence on March 19.
Acquisition returns and cost of capital
In its analysis, Barclays estimated post-tax returns on capital of 6.9% for the fiscal 2024 acquisition cohort and 8.6% for the fiscal 2025 cohort. These figures compare to Barclays’ cost of capital estimates of 10.2% and 9.7% for those same years, respectively.
By contrast, the H1 fiscal 2026 cohort was modelled to exceed the threshold at entry, producing an estimated return of 12.3% against a cost of capital of 9.2%, according to Barclays.
Barclays further noted that for the fiscal 2024 cohort to surpass the cost of capital over the three-year earn-out period at maximum earn-outs, revenue and EBITDA would need to compound at annual rates of 7.3% and 19.4% through fiscal 2027. Those required growth rates sit above Barclays’ own group-level forecasts, which assume 5.2% revenue growth and 5.8% EBITDA growth.
Management commentary and execution risk
Management told investors at the H1 2026 results presentation that investments deliver positive returns "over the longer term" and that "cost synergies that are starting to be delivered, but overall they’re not that significant at the moment." Barclays flagged execution risk as elevated following the November 2025 departure of Australia managing director Graeme Cramb to rival Medivet, calling the move notable at a critical phase of the company’s expansion in Australia.
Barclays also reminded investors that CVS previously recorded a A320 million loss on discontinued operations related to exits from the Netherlands and the Republic of Ireland.
Regulatory backdrop and market share
The Competition and Markets Authority probe into parts of the sector is expected to conclude formally in spring 2026. Barclays observed that the CMAs October 2025 provisional remedies did not include any forced divestments. According to CMA data cited by Barclays, CVS holds roughly 9% of the UK small animal first-opinion practice market, compared with IVC Evidensias roughly 20% share.
Constraints on seizing post-CMA opportunities
Barclays identified four constraints that could limit CVSs ability to capitalise on acquisition opportunities that may arise after the CMA process: heightened regulatory scrutiny; competition from private equity-backed rivals; the potential unattractiveness of CVSs wholly owned operating model versus partnership structures offered by competitors; and workforce sentiment metrics that, despite improvement, are not best-in-class against peers.
Peer comparison and leverage
Barclays highlighted divergence in growth and leverage between CVS and a peer consolidator. VetPartners expanded revenue at a compound annual rate of 25.6% and EBITDA at 21.1% between fiscal 2021 and 2024 while operating at net leverage of 7.2 times. Over the same period CVS grew revenue at 8.3% and EBITDA at 9.3% with net leverage of 1.3 times, based on Companies House filings cited by Barclays.
Earnings forecasts and valuation
Barclays projected adjusted earnings per share of 83.8 pence in fiscal 2026, rising to 110.4 pence by fiscal 2028. This represents a compound annual growth rate of 11.3% from fiscal 2025s 80.1 pence. Barclays contrasted its fiscal 2026 EPS projection with the Bloomberg consensus of 87.4 pence for that year.
The 1,340 pence price target corresponds to a multiple of 16 times fiscal 2026 earnings, which Barclays noted is a discount to the roughly 18 times five-year average. The broker set an upside scenario at 1,570 pence and a downside case at 1,075 pence.
Brokerage disclosure
Barclays disclosed that it is a liquidity provider in CVS securities and has received non-investment banking compensation from the company in the past 12 months.